

STATUTORY RULES

1970 No.

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1970.*

WHEREAS it is provided by sub-section (4.) of section 101 of the *National Health Act 1953-1970* that a drug or medicinal preparation that was not a pharmaceutical benefit under the *National Health Act 1953-1958* immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS that Committee has recommended to the Minister that the following additional drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the *National Health Act 1953-1970*, namely, the drugs and medicinal preparations inserted in the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations by regulation 4 and the Second Schedule to these Regulations:

NOW THEREFORE I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the *National Health Act 1953-1970*.

Dated this *twenty-ninth*
day of *July*, 1970.

Paul Hasluck
Governor-General.

By His Excellency's Command,

(SGD.) A. J. FORBES

Minister of State for Health.

AMENDMENTS OF THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS†

1. These Regulations shall come into operation on the first day of August, 1970. Commencement.
2. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended— First Schedule.
 - (a) by inserting after item 12, the following item:—
" 12A. Antazoline Tablets ";
 - (b) by inserting after item 23, the following item:—
" 23AA. Bemegrade Injection ";
 - (c) by inserting after item 76 the following items:—
" 76AA. Corticotrophin Injection
76AB. Corticotrophin Gelatin Injection
76AC. Corticotrophin Zinc Hydroxide Injection ";

* Notified in the *Commonwealth Gazette* on 1970.

† Statutory Rules 1960, No. 17, as amended by Statutory Rules 1960, Nos. 90 and 102; 1961, Nos. 59 and 137; 1962, Nos. 34, 101 and 114; 1963, Nos. 34, 69 and 107; 1964, Nos. 12, 57 and 135; 1965, Nos. 51, 151 and 152; 1966, Nos. 80 and 144; 1967, Nos. 67, 116 and 158; 1968, Nos. 44, 76, 88 and 146; 1969, Nos. 44, 107 and 185; and 1970, No. .

(d) by omitting item 95; and

(e) by omitting item 418.

3. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the First Schedule to these Regulations. Second Schedule.

4. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Second Schedule to these Regulations. Third Schedule.

5. The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is repealed and the following Schedule is inserted in its stead:— Fifth Schedule.

FIFTH SCHEDULE

Regulation 14.

PHARMACEUTICAL BENEFITS THE PRESCRIBING OF WHICH IS SUBJECT TO CONDITIONS AND RESTRICTIONS

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
1	Acetylcysteine	Cystic Fibrosis (mucoviscidosis)
2	(1) Aspirin with Paracetamol and Caffeine Tablets (2) Aspirin with Codeine Phosphate and Pentobarbitone Sodium Tablets	Any disease or condition in a pensioner
3	Acrylic Resin	Ileostomy or colostomy conditions
4	Albumaid XP	With the written authority of the Director-General, Phenylketonuria
5	Aldosterone	With the written authority of the Director-General, treatment of an acute crisis in adrenal cortical hypofunction (including Addison's disease and salt-losing congenital adrenal hypoplasia)
6	Alprenolol Hydrochloride Injection	Idiopathic hypertrophic subaortic stenosis Right ventricular outflow tract obstruction Dissecting aneurysm, aortic The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
7	Alprenolol Hydrochloride Tablets	Idiopathic hypertrophic subaortic stenosis Right ventricular outflow tract obstruction Dissecting aneurysm, aortic The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents Serious arrhythmias Thyrotoxicosis
8	Ambenonium Chloride	Myasthenia gravis
9	Aminocaproic Acid	Any disease or condition in a patient receiving treat- ment in or at an approved hospital
10	Aminosalicyclic Acid	Tuberculosis
11	Amphotericin B Injection	Systemic mycoses
12	(1) Amphotericin B Tablets (2) Amphotericin B Lozenges (3) Amphotericin B Suspension	Moniliasis

National Health (Pharmaceutical Benefits) Regulations

3

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
13	(1) Ampicillin Capsules, B.P. . . (2) Ampicillin Injections, Tablets and Suspension	Infections of the ear or respiratory tract where they cannot be safely and effectively treated with sulphonamides, phenoxymethylpenicillin or phenethicillin Gram-negative infections where ampicillin appears to be the most suitable drug Any bacterial infection of the genito-urinary tract which cannot be safely or effectively treated with sulphonamides Broad spectrum antibiotic treatment of patients undergoing steroid therapy or recently subjected to steroid therapy Pancreatitis Meningitis Any infection in a pregnant woman or a child that cannot be treated safely and effectively with sulphonamides, phenoxymethylpenicillin or phenethicillin
14	Ascorbic Acid Tablets, B.P. . .	Any disease or condition in a pensioner
15	Azathioprine	With the written authority of the Director-General, azathioprine therapy for a person who has been discharged from an approved hospital and received that therapy while a patient in the hospital
16	Beclamide	Any disease or condition in a patient receiving treatment in or at an approved hospital
17	Benzathine Penicillin, B.P. . .	Prophylaxis of recurrent streptococcal infections, (including rheumatic fever)
18	Benzoin Compound Tincture, B.P.C. aerosol spray	Ileostomy or colostomy conditions
19	Benzylpenicillin Injection, 5,000,000 units	Bacterial endocarditis or septicaemia
20	(1) Benzylpenicillin Tablets, B.P.	Prophylaxis of recurrent streptococcal infections, (including rheumatic fever)
21	(2) Benzylpenicillin Capsules Benzylpenicillin Injection, 10,000,000 units	Bacterial endocarditis or septicaemia Gastrointestinal surgery
22	(1) Benzylpenicillin with Streptomycin Sulphate (2) Benzylpenicillin with Procaine Penicillin and Streptomycin Sulphate	Endocarditis due to streptococcus faecalis or streptococcus viridans
23	Betahistine Hydrochloride . .	Meniere's Syndrome
24	(1) Betamethasone Acetate and Betamethasone Injection (2) Betamethasone Sodium Phosphate Injection, B.P.	Intra-articular use With the written authority of the Director-General, Pre-operative and post-operative prophylactic therapy for those patients undergoing or recently subjected to steroid therapy
25	Buclosamide with Salicylic Acid . .	For the treatment of diseases of the ear
26	Buclosamide, Salicylic Acid and Hydrocortisone Acetate	For the treatment of diseases of the ear
27	Busulphan Tablets, B.P. . .	Treatment in malignant neoplasia
28	(1) Calciferol Tablets, Strong, B.P. (2) Calciferol, B.P.	Any disease or condition in a pensioner With the written authority of the Director-General— Hypoparathyroidism Osteomalacia following gastrectomy Vitamin D-resistant rickets
29	Calcium Aminosalicylate . .	Tuberculosis
30	Capreomycin Sulphate . .	Tuberculosis
31	Carbamazepine	Epilepsy Trigeminal neuralgia
32	Carbenicillin Sodium	With written authority of the Director-General, infections where positive bacteriological evidence confirms that carbenicillin is the most appropriate therapeutic agent

National Health (Pharmaceutical Benefits) Regulations

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
33	Carbenoxolone Sodium ..	Any disease or condition in a patient receiving treatment in or at an approved hospital
34	Cephaloridine	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that cephaloridine is the most appropriate therapeutic agent
35	Cephalothin Sodium	Any disease or condition in a patient receiving treatment in or at an approved hospital
36	Charcoal Tablets	Ileostomy or colostomy conditions
37	Chlorambucil Tablets, B.P. ..	Treatment in malignant neoplasia
38	Chloramine Deodorant Tablets and Powder	Ileostomy or colostomy conditions
39	(1) Chloramphenicol Capsules, B.P. (2) Chloramphenicol Injections .. (3) Chloramphenicol Oral Suspension	Bacterial meningitis Intraocular infections Rickettsioses Typhoid The treatment of other serious infections in a patient where it is established by appropriate bacteriological testing that Chloramphenicol is the only suitable antibiotic listed as a pharmaceutical benefit for use in treating the infection in the patient
40	Chlorotrianisene Tablets ..	Carcinoma of the prostate
41	(1) Chlorpromazine Hydrochloride, B.P. (2) Chlorpromazine Injection, B.P. (3) Chlorpromazine Tablets, B.P.	Any disease or condition in a pensioner The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, B.P., Chlorpromazine Injection, B.P. or Chlorpromazine Tablets, B.P. With the written authority of the Director-General— Hereditary chorea (Huntington's) Malignant neoplasia (late stage) Radiation sickness The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
42	Cholestyramine	With the written authority of the Director-General— Pruritis associated with partial biliary obstruction not responding to other therapy Initial treatment with cholestyramine of proven hyperbetalipoproteinaemia (type II) not responding to other therapy A second or subsequent course of treatment for proven hyperbetalipoproteinaemia (type II) in patients who respond to treatment with cholestyramine but do not respond to other therapy
43	Clofibrate	With the written authority of the Director-General— Diabetic retinopathy (exudative) Initial treatment with clofibrate of hyperlipidaemia not responding to dietary therapy A second or subsequent course of treatment for hyperlipidaemia where significant lowering of serum cholesterol subsequent to initial treatment with clofibrate has been established by laboratory report
44	(1) Cloxacillin Sodium, B.P. .. (2) Cloxacillin Capsules, B.P.	With the written authority of the Director-General, life threatening infection where bacteriological evidence confirms the presence of penicillinase-producing staphylococci

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
45	(1) Codeine Phosphate with Aspirin Soluble Tablets (2) Codeine Phosphate with Aspirin Tablets (3) Codeine Phosphate with Aspirin and Paracetamol soluble Tablets (4) Codeine Phosphate with Aspirin and Paracetamol Tablets (5) Codeine Phosphate with Aspirin, Paracetamol and Caffeine Tablets	Any disease or condition in a pensioner
46	Cod Liver Oil Emulsion ..	Any disease or condition in a child under the age of twelve years or in a pensioner
47	Colistin Sulphomethate Sodium, B.P., for injection	Pyocyanus infection, other gram-negative infections where no other drug is effective
48	Cyanocobalamin Injection, B.P..	Pernicious anaemia and other proven Vitamin B-12 deficiencies Post gastrectomy treatment Sub-acute combined degeneration of the cord Neuroblastoma
49	(1) Cycloserine Tablets, B.P. .. (2) Cycloserine Capsules, B.P. ..	Tuberculosis
50	Cymogran	With the written authority of the Director-General, phenylketonuria
51	(1) Cyproheptadine Hydrochloride, B.P.	Allergic rhinitis Allergic dermatoses
52	(2) Cyproheptadine Tablets, B.P. Cytosine Arabinoside Hydrochloride	Any disease or condition in a patient receiving treatment in or at an approved hospital
53	(1) Deodorant Detergent Solution (Terric N.8 with Spearmint Oil and Cetrimide) (2) Deodorant Detergent Solution (Lauryldimethyl Benzyl Ammonium Chloride and Terric N.8)	Ileostomy or colostomy conditions
54	(1) Deoxycortone Acetate Injection, B.P. (2) Deoxycortone Privalate Injection, B.P. (3) Deoxycortone Acetate Implants, B.P. (4) Deoxycortone Acetate Tablets	Adrenal cortical hypofunction including Addison's disease Total adrenalectomy
55	Desferrioxamine	Acute iron poisoning Hepatolenticular degeneration
56	Dexamethasone Sodium Phosphate Injections	Intra-articular use Cerebral oedema
57	(1) Dextromoramide Tablets, B.P. (2) Dextromoramide Tartrate, B.P.	Treatment in malignant neoplasia
58	Diazepam Injection	Any disease or condition in a pensioner Electrical conversion of cardiac arrhythmias (cardioversion) Endoscopy Epilepsy Minor operative procedures Motor neurone lesion Premedication induction of anaesthesia The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Diazepam

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
58— <i>contd</i>		<p>With the written authority of the Director-General— Hereditary chorea (Huntington's) Malignant neoplasia (late stage) Radiation sickness The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital</p>
59	Diazepam Syrup and 10 mg. Tablets	<p>Any disease or condition in a pensioner Epilepsy Motor neurone lesion The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Diazepam</p>
60	Diazepam Tablets 2 mg. and 5 mg.	<p>With the written authority of the Director-General— Hereditary chorea (Huntington's) Malignant neoplasia (late stage) Radiation sickness The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital Any disease or condition in a pensioner Epilepsy Motor neurone lesion Multiple sclerosis Stiff-man syndrome The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Diazepam</p>
61	Dicyclomine Hydrochloride with Doxylamine Succinate and Pyridoxine Hydrochloride	<p>With the written authority of the Director-General— Hereditary chorea (Huntington's) Malignant neoplasia (late stage) Radiation sickness The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital Vomiting in pregnancy</p>
62	Dienoestrol Cream	Any disease or condition in a pensioner
63	Diethanolamine Fusidate, B.P.C.	<p>With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Diethanolamine Fusidate is the only appropriate antibiotic that is listed as a benefit</p>
64	(1) Dihydroergotoxine Mesylate tablets (2) Dihydroergotoxine Mesylate injection	For the treatment of patients who have suffered an attack of paralytic poliomyelitis
65	Dihydrotachysterol	Hypoparathyroidism
66	Diloxanide Furoate Tablets, B.P.	Intestinal amoebiasis
67	Dimethicone Aerosol Spray ..	Ileostomy or colostomy conditions

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
68	Dimethicone Creams	Use with surgical appliances
69	Dioctyl Sodium Sulphosuccinate with Danthron	Any disease or condition in a pensioner
70	Disodium Cromoglycate	With the written authority of the Director-General— The prevention of asthma for a patient who is under 18 years of age, whose attacks of asthma have been sufficiently severe and frequent to interfere seriously with his normal activities of life and whose re-occurrences of asthma could not be controlled by adequate use of bronchodilators and other standard means of prevention and treatment The prevention of asthma for a patient whose attacks of asthma have been sufficiently severe and frequent to interfere seriously with his normal activities of life and to require the continuous use of over 7.5 mg. of prednisone, or its equivalent, daily or who suffers from a disease indicating that corticosteroid therapy should not be applied, such as peptic ulcer, hypertension of 180/100 or more before treatment, diabetes, osteoporosis proven by X-ray or steroid-induced myopathy
71	Ditophal	Leprosy
72	Droperidol	Lupus vulgaris Any disease or condition in a patient receiving treatment in or at an approved hospital
73	(1) Erythromycin Estolate Capsules, B.P. (2) Erythromycin Estolate, B.P. .. (3) Erythromycin Tablets, B.P. (4) Erythromycin Ethyl Succinate (5) Erythromycin Glucoheptonate (6) Erythromycin Lactobionate .. (7) Erythromycin Stearate, B.P. .. (8) Erythromycin Stearate Tablets, B.P.	Amoebiasis Brucellosis Leptospirosis Lymphogranuloma venereum Pneumonia due to mycoplasma pneumoniae Psittacosis Rickettsioses Staphylococcal septicaemia or staphylococcal pneumonia Actinomycosis, trachoma, or any bacterial or spirochaetal infections where these cannot be safely and effectively treated with sulphonamides, phenoxymethylpenicillin or phenethicillin
74	Ethacrynic Acid	Fluid retention associated with heart failure, cirrhosis of the liver or nephrotic syndrome Fluid retention associated with other conditions and not responding to thiazides
75	Ethinylestradiol Tablets, B.P. ..	Any disease or condition in a pensioner Carcinoma of the prostate Hereditary telangiectasis Premature menopause that is surgically induced Turner's syndrome
76	Ethionamide	Tuberculosis
77	Ethisterone Tablets, B.P. ..	Turner's syndrome
78	Ethylloctenol	With the written authority of the Director-General— Intermittent use for corticosteroid-induced osteoporosis Intermittent use for patients on long term treatment with corticosteroids Osteomalacia following gastrectomy
79	Fludrocortisone Tablets, B.P. ..	Adrenal cortical hypoplasia including Addison's disease Total adrenalectomy
80	Flufenamic Acid	Any disease or condition in a patient receiving treatment in or at an approved hospital
81	Fluorouracil Sodium	Treatment in malignant neoplasia

National Health (Pharmaceutical Benefits) Regulations

8

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
82	Fluoxymesterone Tablets, B.P. . .	Eunuchism Eunuchoidism Carcinoma of the breast With the written authority of the Director-General— Intermittent use for corticosteroid-induced osteoporosis Proven aplastic anaemias
83	Fluphenazine Enanthate . . .	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits— Fluphenazine Enanthate Fluphenazine Hydrochloride With the written authority of the Director-General— Hereditary chorea (Huntington's) Malignant neoplasia (late stage) Radiation sickness The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
84	Fluphenazine Hydrochloride . . .	Any disease or condition in a pensioner The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits— Fluphenazine Enanthate Fluphenazine Hydrochloride With the written authority of the Director-General— Hereditary chorea (Huntington's) Malignant neoplasia (late stage) Radiation sickness The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
85	(1) Folic Acid, B.P.	Proven folic acid deficiency
	(2) Folic Acid Tablets, B.P. 5 mg.	Sprue or the sprue-like syndrome
86	Folic Acid Tablets, B.P. 0.5 mg.	Pregnancy
87	Framycetin Sulphate Tablets . . .	Bowel sterilization preparatory to major surgery
88	Fruzemide Tablets, B.P.	Fluid retention associated with heart failure, cirrhosis of the liver or nephrotic syndrome Fluid retention associated with other conditions and not responding to thiazides
89	Galactomin Formula No. 17	With the written authority of the Director-General— Galactosaemia Conditions needing an extreme restriction of lactose in the diet of a patient under the age of four years
90	Galactomin Formula No. 19	With the written authority of the Director-General, glucose-galactose malabsorption
91	Gentamicin Sulphate	Any disease or condition in a patient receiving treatment in or at an approved hospital
92	Glucose Indicator—Blood	With the written authority of the Director-General, diabetes mellitus in which adequate control is impossible by any other means because of low renal threshold

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
93	Goat's Milk, Dehydrated ..	With the written authority of the Director-General, cow's milk allergy in children under the age of four years
94	Goat's Milk, Whole (Sterilized) ..	With the written authority of the Director-General, cow's milk allergy in children under the age of four years
95	Griseofulvin Tablets, B.P. ..	With the written authority of the Director-General, for use in severe tinea infections due to <i>Microsporum</i> , <i>Trichophyton</i> or <i>Epidermophyton</i> species which have been proven by laboratory examination or Wood's Light
96	Guanacine Tablets	Any disease or condition in a patient receiving treatment in or at an approved hospital
97	Halibut Liver Oil Capsules ..	Any disease or condition in a pensioner
98	Haloperidol	Any disease or condition in a pensioner The treatment of a mental disorder in a person who has after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Haloperidol With the written authority of the Director-General— Hereditary chorea (Huntington's) Malignant neoplasia (late stage) Radiation sickness The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
99	(1) Hexachlorophane with Chloroxylenol (2) Hexachlorophane with Entsu- fon (3) Hexachlorophane with Lissapol (4) Hexachlorophane in Soap Solution	Any disease or condition in a patient receiving treatment in or at an approved hospital
100	Hydrocortisone Acetate Injection, B.P.	Intra-articular use
101	Hydrocortisone Sodium Succinate Injection	Acute adrenal cortical hypofunction due to medical or surgical crisis Prophylactic therapy before, during and after surgical procedures for patients undergoing or recently subjected to steroid therapy Stevens-Johnson disease
102	Hydroxocobalamin Injection, B.P.	Pernicious anaemia and other proven Vitamin B-12 deficiencies Post gastrectomy treatment Sub-acute combined degeneration of the cord Neuroblastoma
103	Hydroxyprogesterone Caproate ..	Carcinoma of the endometrium Progesterone deficiency proved by hormonal assay, by lateral wall smear or by endometrial biopsy
104	Idoxuridine	Infections caused by Herpes Simplex Virus
105	Influenza Vaccine	For prophylaxis of pensioners only
106	Insect Allergen Extract—Honey Bee	With the written authority of the Director-General, severe constitutional reaction to bee stings
107	Insect Allergen Extract—Paper Wasp	With the written authority of the Director-General, severe constitutional reaction to wasp stings
108	Isoniazid Tablets, B.P. . . .	Tuberculosis
109	Isoprenaline Hydrochloride Tablets, 30 mg.	Stokes-Adams syndrome

National Health (Pharmaceutical Benefits) Regulations

10

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
110	Kanamycin Sulphate Capsules, Injections and Oral Solution	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Kanamycin Sulphate is the most appropriate antibiotic
111	Kitasamycin	Any disease or condition in a patient receiving treatment in or at an approved hospital
112	Leucovorin	Antidote to folic acid antagonists
113	Levorphanol Tartrate	Obstetrical use
114	Lignocaine Injection, B.P.	Severe intractable pain
115	Lincomycin Hydrochloride	Cardiac arrhythmias Gram positive coccal infections where these cannot be safely and effectively treated with penicillin and where resistance to erythromycin has been established by laboratory investigation
116	Liothyronine Tablets, B.P.	Osteomyelitis
117	Lofenalac	Myxoedema With the written authority of the Director-General, phenylketonuria
118	Lypressin Nasal Spray	Diabetes insipidus
119	Maphenide Acetate	Any disease or condition in a patient receiving treatment in or at an approved hospital
120	Medroxyprogesterone Acetate Tablets, 2.5 mg.	Carcinoma of the endometrium
121	Medroxyprogesterone Acetate Tablets, 10 mg.	Precocious puberty
122	Medroxyprogesterone Acetate Tablets, 100 mg.	Carcinoma of the breast Carcinoma of the endometrium
123	Medroxyprogesterone Acetate Injections	Hypernephroma Carcinoma of the endometrium Hypernephroma
124	Melphalan	Progesterone deficiency proven by hormonal assay, by lateral wall smear or by endometrial biopsy
125	Mercaptopurine Tablets, B.P.	Treatment in malignant neoplasia Allergic granulomatous angiitis Lupus erythematosus Nephrotic syndrome Periarteritis (Nodosa)
126	(1) Methandienone Tablets, B.P. (2) Methenolone Acetate	Treatment in malignant neoplasia
127	Methicillin Sodium, B.P. for Injection	With the written authority of the Director-General— Intermittent use for corticosteroid-induced osteoporosis Intermittent use for patients on long-term treatment with corticosteroids
128	Methotrexate Tablets	Proven or suspected staphylococcal septicaemia
129	Methotrexate Injections	Treatment in neoplastic disease
130	Methylprednisolone Acetate Injection	Treatment in neoplastic disease
131	(1) Methyltestosterone Tablets, B.P. (2) Methyltestosterone, B.P.	Intra-articular use
132	Methysergide Maleate	Carcinoma of the breast Eunuchism Eunuchoidism Klinefelter's syndrome (seminiferous tubule dysgenesis)
133	Metyrapone	Treatment of severe recalcitrant migraine where other treatment has failed
134	Minafen	Any disease or condition in a patient receiving treatment in or at an approved hospital
135	Morphine Sulphate, B.P. with Tacrine Tablets	With the written authority of the Director-General, phenylketonuria
136	Mustine Hydrochloride Injection	Severe intractable pain Treatment in malignant neoplasia

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
137	Nalidixic Acid	Urinary tract infections where positive bacteriological evidence shows sulphonamides to be ineffective
138	Nandrolone Decanoate	Carcinoma of the breast With the written authority of the Director-General— Intermittent use for corticosteroid-induced osteoporosis Intermittent use for patients on long-term treatment with corticosteroids Severe osteoporosis due to proven pancreatitis
139	Nandrolone Hexoxyphenyl Propionate	Carcinoma of the breast With the written authority of the Director-General— Intermittent use for corticosteroid-induced osteoporosis Intermittent use for patients on long-term treatment with corticosteroids
140	Nandrolone Phenylpropionate Injection, B.P.	Carcinoma of the breast With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
141	(1) Natamycin Oral Tablets	Moniliasis
	(2) Natamycin Oral Suspension	
142	Neomycin Sulphate Powder	With the written authority of the Director-General, use by inhalation in cystic fibrosis (mucoviscidosis)
143	Neomycin Tablets, B.P.	Bowel sterilization preparatory to major surgery Encephalopathy, hepatic
144	Nicotinic Acid Tablets, B.P.	Any disease or condition in a pensioner
145	Nitrazepam	Myoclonic epilepsy
146	(1) Nitrofurantoin Tablets, B.P.	Urinary tract infections where positive bacteriological evidence shows sulphonamides to be ineffective
	(2) Nitrofurantoin Oral Suspension	
147	Nitromin	Treatment in malignant neoplasia
148	Norethisterone Acetate, B.P.	Carcinoma of the breast
149	Nutramigen	With the written authority of the Director-General— Cow's milk allergy in children under the age of four years Cystic Fibrosis (mucoviscidosis) Galactosaemia Lactose intolerance
150	Nystatin Tablets, B.P.	Moniliasis
151	Orciprenaline Sulphate Injection	Any disease or condition in a patient receiving treatment in or at an approved hospital
152	Oxprenolol Hydrochloride Tablets, 20 mg and 40 mg	With the written authority of the Director-General— Idiopathic hypertrophic subaortic stenosis Right ventricular outflow tract obstruction Dissecting aneurysm, aortic The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents Serious arrhythmias Thyrotoxicosis
153	Oxprenolol Hydrochloride Injection	Idiopathic hypertrophic subaortic stenosis Right ventricular outflow tract obstruction Dissecting aneurysm, aortic The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents Serious arrhythmias Thyrotoxicosis

National Health (Pharmaceutical Benefits) Regulations

12

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
154	Oxycodone Pectinate	Treatment in malignant neoplasia
155	Oxymetholone	With the written authority of the Director-General, proven aplastic or hypoplastic anaemias (familial)
156	(1) Pancreatin, B.P. (2) Pancreatin Enzyme 4 X U.S.N.F. XII (3) Pancrelipase	Cystic Fibrosis (mucoviscidosis) Following pancreatico-duodenectomy Pancreatic steatorrhoea
157	(1) Paracetamol Suspension .. (2) Paracetamol Tablets, B.P.	Any disease or condition in a pensioner
158	Paracetamol with Codeine Phosphate and Pentobarbitone Sodium	Any disease or condition in a pensioner
159	(1) Paraffin Liquid Emulsion .. (2) Paraffin Liquid Emulsion with Phenolphthalein	Any disease or condition in a pensioner
160	Pargyline Hydrochloride ..	Any disease or condition in a patient receiving treatment in or at an approved hospital
161	Penicillamine	With the written authority of the Director-General— Acute heavy metal intoxication Cystinosis Cystinuria with calculus formation Haemoglobinuria, paroxysmal cold Wilson's disease (hepatolenticular degeneration)
162	Pethidine Hydrochloride with Levallorphan Tartrate	Obstetric use
163	Phytomenadione Injection, B.P., 10 mg. per ml.	Antidote to anticoagulants Haemorrhagic diathesis associated with malabsorption
164	Phytomenadione Injection, B.P., 1 mg. in 1 ml.	Antidote to anticoagulants Suspected cerebral trauma of the new born Haemorrhagic diathesis associated with malabsorption Haemorrhagic disease of the new born
165	Pituitary, Posterior Lobe, Insufflation	Diabetes insipidus
166	Plasma Substitute (Polypeptide) ..	Any disease or condition in a patient receiving treatment in or at an approved hospital
167	Polymyxin B. Sulphate Powder ..	With the written authority of the Director-General, use by inhalation in cystic fibrosis (mucoviscidosis)
168	Polyoestradiol Phosphate ..	Carcinoma of the breast Carcinoma of the prostate
169	Prednisolone Sodium Phosphate Retention Enema and Suppository	With the written authority of the Director-General— Ulcerative colitis proven by sigmoidoscopy or radiological report Proctitis proven by sigmoidoscopy
170	(1) Prednisolone Acetate Injection (2) Prednisolone Butyl Acetate Injection	Intra-articular use
171	Prednisolone Sodium Succinate Injection	Acute adrenal cortical hypofunction due to any medical or surgical crises Prophylactic therapy before, during and after surgical procedures for patients undergoing or recently subject to steroid therapy Stevens-Johnson disease
172	Procarbazine Hydrochloride ..	Treatment in malignant neoplasia
173	(1) Prochlorperazine (2) Prochlorperazine Tablets, B.P.	Meniere's Syndrome
174	Progesterone	Progesterone deficiency proven by hormonal assay, by lateral wall smear or by endometrial biopsy
175	Propranolol Injection, B.P. ..	Idiopathic hypertrophic subaortic stenosis Right ventricular outflow tract obstruction Dissecting aneurysm, aortic

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
175— <i>contd</i>		The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
176	Propranolol Tablets, B.P.	Serious arrhythmias Thyrotoxicosis With the written authority of the Director-General— Idiopathic hypertrophic subaortic stenosis Right ventricular outflow tract obstruction Dissecting aneurysm, aortic The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents Serious arrhythmias Thyrotoxicosis
177	Prosobee	With the written authority of the Director-General— Galactosaemia Homocystinuria Lactose intolerance Milk allergy in children under the age of four years
178	Pyrazinamide	Any disease or condition in a patient receiving treatment in or at an approved hospital
179	(1) Pyridostigmine Injection, B.P. (2) Pyridostigmine Tablets, B.P.	Myasthenia gravis
180	Pyridoxine Hydrochloride Tablets	Homocystinuria Radiation sickness Treatment and prophylaxis of peripheral neuritis caused or likely to be caused by isoniazid therapy Sideroblastic (refractory anaemia)
181	Pyrimethamine Tablets	Toxoplasmosis Malaria
182	(1) Riboflavine Tablets (2) Senna Fruit Extract (standardised)	Any disease or condition in a pensioner
183	Sobee	With the written authority of the Director-General— Galactosaemia Homocystinuria Lactose intolerance Milk allergy in children under the age of four years
184	(1) Sodium Aminosalicylate Tablets, B.P. (2) Sodium Aminosalicylate Injection (3) Sodium Aminosalicylate Cachets (4) Sodium Aminosalicylate Granules (5) Sodium Aminosalicylate with Isoniazid, B.P.	Tuberculosis
185	Sodium Folate	Proven folic acid deficiency Sprue or the sprue-like syndrome
186	Sodium Fusidate	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Sodium Fusidate is the only appropriate antibiotic that is listed as a benefit
187	Soyalac	With the written authority of the Director-General— Galactosaemia Homocystinuria Lactose intolerance Milk allergy in children under the age of four years

National Health (Pharmaceutical Benefits) Regulations

14

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
188	Spiramycin	Staphylococcal septicaemia or staphylococcal pneumonia Toxoplasmosis, active-serologically proven Any gram-positive bacterial infections where these cannot be treated safely and effectively by sulphonamides or penicillins
189	Spirolactone Tablets, B.P. ..	With the written authority of the Director-General— To supplement other diuretics when these have proved inadequate
190	Stanolone	Myasthenia gravis Carcinoma of the breast With the written authority of the Director-General— Intermittent use for corticosteroid-induced osteoporosis Intermittent use for patients on long-term treatment with corticosteroids
191	Stanozolol	With the written authority of the Director-General— Intermittent use for corticosteroid-induced osteoporosis Intermittent use for patients on long-term treatment with corticosteroids
192	Stilboestrol Diphosphate ..	Carcinoma of the prostate
193	Streptokinase	Any disease or condition in a patient receiving treatment in or at an approved hospital
194	Sulphasalazine	Ulcerative colitis
195	Sulthiame	Epilepsy where other anticonvulsants have failed
196	(1) Surgical Cement (2) Surgical Cement Solvent	Ileostomy or colostomy conditions For use with surgical appliances
197	(1) Sustanon (2) Testosterone Implants, B.P. (3) Testosterone Enanthate (4) Testosterone Propionate Injection, B.P.	Eunuchoidism Eunuchism Klinefelter's syndrome (seminiferous tubule dysgenesis) Carcinoma of the breast
198	Tetanus Antitoxin, B.P. (Bovine)	Patients who have previously received an injection of equine serum
199	(1) Thiambutosine Tablets, B.P. .. (2) Thiambutosine Injection	Leprosy
200	Thiamine Hydrochloride Tablets, B.P.	Any disease or condition in a pensioner
201	Thiethylperazine Tablets and Suppositories	Radiation sickness Nausea resulting from cytotoxic therapy
202	(1) Thioridazine Tablets, B.P. .. (2) Thioridazine	Any disease or condition in a pensioner The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits— Thioridazine Thioridazine Tablets, B.P. With the written authority of the Director-General— Hereditary chorea (Huntington's) Malignant neoplasia (late stage) Radiation sickness The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
203	Thyrotrophin	Any disease or condition in a patient receiving treatment in or at an approved hospital
204	Tragacanth, Indian (Gum Karaya)	Ileostomy or colostomy conditions

National Health (Pharmaceutical Benefits) Regulations

15

FIFTH SCHEDULE—continued

First Column Item No.	Second Column Pharmaceutical Benefit	Third Column Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
205	Trasylol	Any disease or condition in a patient receiving treatment in or at an approved hospital
206	Tretamine	Treatment in malignant neoplasia
207	Triacetyloleandomycin	Amoebiasis Brucellosis Leptospirosis Lymphogranuloma venereum Pneumonia due to mycoplasma pneumoniae Pneumonia, staphylococcal Psittacosis Rickettsioses Staphylococcal septicaemia Actinomycosis, Trachoma, or any bacterial or spirochaetal infections where these cannot be safely and effectively treated by sulphonamides, phenoxymethylpenicillin or phenethicillin
208	(1) Trifluoperazine Tablets, B.P. . . (2) Trifluoperazine Hydrochloride, B.P.	Any disease or condition in a pensioner The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Trifluoperazine Hydrochloride, B.P. or Trifluoperazine Tablets, B.P. With the written authority of the Director-General— Hereditary chorea (Huntington's) Malignant neoplasia (late stage) Radiation sickness The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
209	Triglyde	With the written authority of the Director-General, proven malabsorption
210	Trimetaphan Injection, B.P. ..	Hypotensive in anaesthesia
211	Trimethoprim with Sulphamethoxazole	Any disease or condition in a patient receiving treatment in or at an approved hospital
212	Vadrine	Any disease or condition in a patient receiving treatment in or at an approved hospital
213	Velactin	With the written authority of the Director-General— Galactosaemia Homocystinuria Lactose intolerance Milk allergy in children under the age of four years
214	(1) Vinblastine Sulphate (2) Vincristine Sulphate	Treatment in malignant neoplasia
215	Vinyl Pyrrolidone and Vinyl Acetate with Benzocaine Aerosol Spray	Ileostomy or colostomy conditions
216	(1) Viomycin Sulphate (2) Viomycin Sulphate Injection, B.P.	Tuberculosis
217	Vitamin A with Thiamine Hydrochloride, Riboflavine, Nicotinamide, Ascorbic Acid and Vitamin D Tablets and Capsules	Any disease or condition in a pensioner

THE SCHEDULES

FIRST SCHEDULE

Regulation 3.

AMENDMENTS OF THE SECOND SCHEDULE TO THE NATIONAL HEALTH
(PHARMACEUTICAL BENEFITS) REGULATIONS

1. Add at the end of item 13 (in the third column)—
"Ferrous Sulphate mixture Prescribers' List
Ferrous Sulphate mixture Prescribers' List, Children's Section".
2. Add at the end of item 91 (in the third column)—
"Neomycin Sulphate with Nystatin, Triamcinolone Acetonide and Gramicidin".
3. Add at the end of item 95 (in the third column)—
"Natamycin with Neomycin Sulphate and Hydrocortisone".
4. Insert in item 125 (in the third column)—
"Neomycin Sulphate with Hydrocortisone and Natamycin".
5. Add at the end of item 126 (in the third column)—
"Gramicidin with Nystatin, Triamcinolone Acetonide and Neomycin Sulphate
Natamycin with Hydrocortisone and Neomycin Sulphate".
6. Add at the end of item 133 (in the third column)—
"Gramicidin with Neomycin Sulphate, Triamcinolone Acetonide and Nystatin".
7. After item 203 insert—

"203A	Triamcinolone Acetonide ..	Gramicidin with Neomycin Sulphate, Nystatin and Triamcinolone Acetonide".
-------	----------------------------	--

SECOND SCHEDULE

Regulation 4.

AMENDMENTS OF THE THIRD SCHEDULE TO THE NATIONAL HEALTH
(PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 75, insert—
"75. Carbenicillin Sodium".
2. After item 80, insert—
"80A. Cephalothin Sodium".
3. After item 91, insert—
"91A. Cholestyramine".
4. Omit item 117, insert—
"117. Desferrioxamine Mesylate".
5. Omit item 136.
6. Omit item 165.
7. After item 186, insert—
"187. Haemodialysis Fluid—Concentrate".
8. After item 197, insert—
"197A. Insect Allergen Extract—Paper Wasp".
9. After item 215, insert—
"215A. Leucovorin".
10. After item 223A, insert—
"223B. Mebeverine Hydrochloride".
11. Omit item 266A, insert—
"266A. Oxprenolol Hydrochloride".
12. Omit items 309 and 310.
13. After item 359, insert—
"359A. Stilboestrol Diphosphate".
14. After item 405, insert—
"405A. Trimipramine Maleate
405B. Trimipramine Mesylate".